Edmond DE Rothschild Holding S.A. Has $47.94 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Edmond DE Rothschild Holding S.A. increased its stake in Edwards Lifesciences Corporation by 2.5%, acquiring an additional 15,861 shares, bringing its total holdings to 661,448 shares.
• Edwards Lifesciences reported a Q2 earnings per share of $0.67, exceeding analysts' estimates, with revenue also surpassing expectations at $1.53 billion.
• Major institutional investors, including Baird Financial Group Inc., significantly boosted their investments in Edwards Lifesciences during the fourth quarter, reflecting strong confidence in the company's stock.

Edmond DE Rothschild Holding S.A. increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 661,448 shares of the medical research company's stock after acquiring an additional 15,861 shares during the period. Edwards Lifesciences makes up approximately 0.8% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 27th biggest holding. Edmond DE Rothschild Holding S.A. owned 0.11% of Edwards Lifesciences worth $47,942,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Quantbot Technologies LP acquired a new position in Edwards Lifesciences in the 1st quarter worth about $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. Finally, Costello Asset Management INC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $29,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Robert W. Baird lifted their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Truist Financial boosted their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Finally, Citigroup restated a "buy" rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.41 during midday trading on Tuesday, reaching $79.80. The company's stock had a trading volume of 1,223,016 shares, compared to its average volume of 4,431,754. The firm has a market capitalization of $46.85 billion, a PE ratio of 11.48, a P/E/G ratio of 3.90 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The stock's 50 day simple moving average is $78.80 and its 200 day simple moving average is $75.26.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.